• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    EyePoint Pharma Q3 2024 Results & Recent Developments

    GLOBENEWSWIRE

    EyePoint Pharmato Participate in Upcoming Investor Conferences

    GLOBENEWSWIRE

    EyePoint Pharma Closes Upsized Offering with Full Option Exercise

    GLOBENEWSWIRE

    EyePoint Pharmaceuticals Prices Upsized Public Offering

    GLOBENEWSWIRE

    EyePoint`s Duravyu bounces back with promising DME data

    FIERCE PHARMA

    EyePoint Pharmaceuticals Plans Public Offering of Common Stock

    #N/A

    EyePoint Announces First Patient Dosed In DURAVYUTM Trial

    GLOBENEWSWIRE

    EyePoint Reports Inducement Grants Under NASDAQ Rule 5635(c)(4)

    GLOBENEWSWIRE

    EyePoint Reports Inducement Grants Under NASDAQ Rule

    GLOBENEWSWIRE

    EyePoint Appoints Fred Hassan To Board Of Directors

    GLOBENEWSWIRE

    EyePoint Receives FDA Warning Letter For Eye Implant Manufacturing Issues

    FIERCE PHARMA

    EyePoint Pharmaceuticals Receives FDA Warning Letter

    FDA

    EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)

    GLOBENEWSWIRE

    EyePoint Pharmaceuticals To Present At H.C. Wainwright Conference

    GLOBENEWSWIRE

    EyePoint Pharmaceuticals Reports Q2 2024 Results And Recent Developments

    GLOBENEWSWIRE

    EyePoint Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)

    GLOBENEWSWIRE

    EyePoint Pharmaceuticals to Highlight DURAVYU (Vorolanib) Clinical Progress

    GLOBENEWSWIRE

    EyePoint To Host R&D Day On June 26, 2024

    GLOBENEWSWIRE

    EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)

    GLOBENEWSWIRE

    EyePoint Pharma: Presenting At Goldman Sachs Healthcare Conference

    GLOBENEWSWIRE

    EyePoint Reports Inducement Grants Under Nasdaq 5635(c)(4)

    GLOBENEWSWIRE

    EyePoint Pharma Q1 2024 Results, Corporate Updates

    GLOBENEWSWIRE

    EyePoint reports Duravyu trial fail, raising questions

    FIERCE PHARMA

    EyePoint`s DURAVYU™ Topline Phase 2 Diabetic Retinopathy Data

    GLOBENEWSWIRE

    Mirae Asset Global Investments Co. Ltd. Purchases 882 Shares of EyePoint

    DEFENSWORLD

    EyePoint Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    EyePoint Expands Scientific Advisory Board with WorldRenowned Retina Specialists

    GLOBENEWSWIRE

    EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    EyePoint Analysts Just Slashed This Year`s Revenue Estimates By 22%

    YAHOO FINANCE

    EyePoint Pharma Reports Fourth Quarter and Full-Year 2023 Financial Results

    GLOBENEWSWIRE

    EyePoint Announces Appointment of Ramiro Ribeiro as Chief Medical Officer

    GLOBENEWSWIRE

    EyePoint to Report Fourth Quarter and Full-Year 2023 Financial Results

    GLOBENEWSWIRE

    EyePoint Pharma Announces Participation at Upcoming Investor Conferences

    GLOBENEWSWIRE

    EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration

    GLOBENEWSWIRE

    EyePoint Pharmaceuticals to Present at 6th Annual Biotechnology Conference

    GLOBENEWSWIRE

    EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    EyePoint Pharma Announces First Patient Dosed in Ph 2 VERONA Trial of EYP-1901

    GLOBENEWSWIRE

    EyePoint to Present at the 42nd Annual J.P. Morgan Healthcare Conference

    GLOBENEWSWIRE

    EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering

    GLOBENEWSWIRE

    EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering

    GLOBENEWSWIRE

    EyePoint Pharma Stock Surges on Phase II Wet AMD-Therapy Results

    BIOSPACE

    EyePoint Pharma Announces Positive Topline Data from the Phase 2 of EYP-1901

    GLOBENEWSWIRE

    EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock

    GLOBENEWSWIRE

    EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    EyePoint Pharmaceuticals Reports Third Quarter 2023 Financial Results

    GLOBENEWSWIRE

    EyePoint to Host Virtual Key Opinion Leader (KOL) Event on November 9, 2023

    GLOBENEWSWIRE

    EyePoint Pharmaceuticals Announces Presentations at Eyecelerator 2023

    GLOBENEWSWIRE

    EyePoint to Report Third Quarter 2023 Financial Results on November 1, 2023

    GLOBENEWSWIRE

    EyePoint Pharmaceuticals Strengthens Board and Executive Leadership Team

    GLOBENEWSWIRE

    EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    EyePoint Reports Positive Update for Lead Product Candidate EYP-1901

    GLOBENEWSWIRE

    EyePoint Announces Participation at Upcoming Investor Conferences

    GLOBENEWSWIRE

    EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    EyePoint to Present at H.C. Wainwright 3rd Annual Ophthalmology Conference

    GLOBENEWSWIRE

    EyePoint Pharmaceuticals Reports Second Quarter 2023 Financial Results

    GLOBENEWSWIRE

    EyePoint Presents Data and Patient Baseline Characteristics for DAVIO 2 Trial

    GLOBENEWSWIRE

    EyePoint to Report Second Quarter 2023 Financial Results on August 2, 2023

    GLOBENEWSWIRE

    EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.